The 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View Abstracts

Breakfast & CME Satellite Symposium

Break

Opening Ceremony

Break between Opening Ceremony and State of the Art Lectures

MASH-related Liver Cancer: Worldwide Epidemiology and Global

AI Applications in Liver Disease and Cancer

Abbreviated MRI and Novel Blood Work Modalities for HCC Surveillance

Enhanced Ultrasound Techniques for HCC Diagnosis

cfDNA Methylation Signature for HCC Detection

Use of AFP in Clinical Practice as a Prognostic Marker for IO Plus Anti-VEGF Therapy in Unresectable HCC

Biomarkers for Diagnosis and Prognostication of HCC: A Pathologist's Perspective

ALBI Scoring in HCC When to ALBI and Why

Management of Viral Hepatitis During HCC Treatment

Neoadjuvant vs Adjuvant Therapy: A Biological Approach

Discussion

Coffee Break & Oral Poster Session

TACE (East vs West Perspective)

Combining Local Ablation With Immunotherapy

Bridging to Surgery Using Yttrium90

TARE: Western Experience TARE: Korean Experience

Downstaging Conversion Therapy of uHCC After Systemic Therapy

Radiation Therapy

Combination Downstaging Therapies in Liver Transplantation for Advanced HCC

Lunch & Non-CE Product Theater

Oral Poster Session

Borderline Resectable HCC

Etiology-Based Checkpoint Inhibitor Therapies

Hepatectomy Following Conversion Therapy Using TKI/PD-1 in Unresectable HCC

Anti-Angiogenic Plus Checkpoint Inhibitor Systemic Therapy

Systemic Treatment for Hepatocellular Carcinoma

Doublet Checkpoint Inhibition as Systemic Therapy

Welcome Luau Dinner on Ocean Lawn

Registration

Breakfast & CME Satellite Symposium: Medical Crossfire: Individualizing Treatment Plans in Advanced Hepatocellular Carcinoma Based on Biology and Other Patient Characteristics

Break between Satellite and General Session

Molecular Pathogenesis of Intrahepatic Cholangiocarcinoma

New Technologies to Study Liver Cancer

Fibrolamellar Carcinoma

Biomarker Research of Combination Immunotherapy in HCC

Immune Heterogeneity and Tumor-Immune Interactions in iCCA

AFP Vaccine and Novel Immune Checkpoint Inhibitors for HCC

Systemic Therapy for Biliary Cancers

Cyanobacteria as a Risk Factor for HCC

The Promotion and Application of the CNLC (ChiNa Liver Cancer) Guidelines for Hepatocellular Carcinoma

Predictors and Management of HCC Recurrence After Liver Transplant

IO Treatment for Transplanted Patients

Robotic Surgery

Impact of Vascular Involvement on Treatment with Checkpoint Inhibitors

Living Donor Transplants for HCC

How to Prevent HCC in Hepatitis B Disease

Surgery Versus Transplant Perspectives

Treatment of Hepatitis B and C in Patients with HCC

Lunch & Non-CE OncLive Seminar: Advancements in the Management of Intermediate and Advanced Hepatocellular Carcinoma (HCC)

Looking Toward Molecular-Stratified Characterization of HCC

Update on Molecular and Pathological Features of Hepatobiliary Tumors

What's Next for Adjuvant and Neoadjuvant Therapy for HCC?

Highlights in Early-Phase Clinical Trials for HCC Therapies

Hepatocellular Carcinoma among Māori in Aotearoa New Zealand: A Genomic Perspective

Outcomes of Patients Receiving Lenvatinib or Atezolizumab Plus Bevacizumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: PRISM Study

Genomic landscape of clinically actionable FGFR alterations in biliary tract cancer and across solid tumors

Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen-Presenting Warriors

Summary of APPLE 2024/Closing Ceremony APPLE 2025 Announcement